U.S. Orthopedic Devices Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: U.S.
- ✓Market: Orthopedic Devices
- ✓Market Size 2024: USD 22.4 billion
- ✓Market Size 2032: USD 36.8 billion
- ✓CAGR: 6.4%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock In Outpatient Contracts: Buyers and investors should lock in ASC-focused implant kit contracts by Q4 2026, before the Inpatient Only phase-out resets procurement terms, since volume is moving to facilities negotiating directly on price. Suppliers lacking outpatient-ready instrument sets will lose share fastest.
U.S. Orthopedic Devices: Market Overview
The U.S. orthopedic devices market generated an estimated USD 22.4 billion in 2024, spanning joint reconstruction implants, spinal fusion systems, trauma fixation, sports medicine, and bone growth stimulators. Private manufacturers dominate design, manufacturing, and distribution, with Stryker, DePuy Synthes, and Zimmer Biomet controlling the largest share of hip and knee revenue. Government's role is primarily as payer and regulator rather than owner, since Medicare and Medicaid finance most procedures through fee schedules and coverage determinations.
Policy has shaped the market's current form in two decisive ways. The Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act created the premarket classification architecture that let implant makers scale through 510(k) clearances. The Medicare Access and CHIP Reauthorization Act of 2015 restructured physician payment and accelerated the shift toward outpatient procedures. Private industry leads on product innovation and surgeon-facing robotics, while government leads on reimbursement and post-market safety surveillance through the FDA's MAUDE database.
Policy-Driven Growth in U.S. Orthopedics
The Inpatient Only list phase-out in the CY2026 Hospital Outpatient Prospective Payment System final rule, administered by the Centers for Medicare and Medicaid Services, moves elective hip and knee arthroplasty toward ambulatory surgery centers. Because ASC payment rates sit below hospital inpatient rates, payers accept the shift and implant volume follows the procedure. Manufacturers supplying outpatient-ready instrument sets capture this demand, expanding the addressable market without requiring new clinical approvals.
The Transitional Coverage for Emerging Technologies pathway, finalized by CMS in August 2024, provides Medicare coverage with evidence development for FDA Breakthrough Devices, capped at five technologies annually. This closes the gap between clearance and reimbursement that previously delayed revenue for novel spinal and augmentation devices. Parallel support comes from MDUFA V under the Medical Device User Fee Amendments for FY2023–FY2027, which sets 90-day FDA review goals for 510(k) submissions and 180-day goals for premarket approvals, accelerating product launches.
Regulatory Barriers and Compliance Costs
Premarket clearance is the first barrier. The FDA's Center for Devices and Radiological Health administers 510(k) and premarket approval pathways under the Federal Food, Drug, and Cosmetic Act, with PMA applicants paying standard application fees above USD 500,000 in FY2025 under MDUFA V. Statutory review clocks of 90 FDA days for 510(k) and 180 days for PMA are routinely extended by additional information requests, commonly delaying launch timelines by six to twelve months.
Environmental and transparency rules add recurring cost. EPA's 2024 amendments to the ethylene oxide sterilizer National Emission Standards for Hazardous Air Pollutants under 40 CFR Part 63 Subpart O require implant suppliers using EO sterilization to install emission controls, with compliance phasing in over several years. Open Payments reporting under Section 6002 of the Affordable Care Act, administered by CMS, requires manufacturers to disclose physician transfers of value, adding annual reporting and audit costs for surgeon-facing commercial teams.
Policy-Created Opportunities in U.S. Orthopedics
Medicare's Transitional Coverage for Emerging Technologies pathway creates a fast-track commercial opportunity for Breakthrough-designated spinal fusion and cartilage repair devices. Developers securing one of five annual TCET slots can convert FDA clearance into Medicare payment within months rather than waiting for standard national coverage timelines. Early-stage suppliers with registry-ready evidence plans gain the most from this structure.
Veterans Affairs procurement offers a second channel. The VA's National Acquisition Center manages Federal Supply Schedule contracts, and the Veterans Health Administration purchases orthopedic implants across its national hospital network under Federal Acquisition Regulation and Buy American Act provisions. Suppliers holding FSS contracts and domestic manufacturing footprints secure predictable volume, while ASC-compatible instrument systems open demand across VA outpatient surgery sites.
Market at a Glance
| Metric | Detail |
|---|---|
| Market Size 2024 | USD 22.4 billion |
| Market Size 2032 | USD 36.8 billion |
| Growth Rate (CAGR) | 6.4% |
| Most Critical Decision Factor | Reimbursement eligibility under CMS coverage and payment rules |
| Largest Region | South Region |
| Competitive Structure | Consolidated oligopoly; top five hold roughly 60% of revenue |
Leading Market Participants
- Stryker Corporation
- DePuy Synthes
- Zimmer Biomet
- Smith & Nephew
- Medtronic
- Globus Medical
- Enovis
- Orthofix Medical
- CONMED Corporation
- Exactech
Regulatory and Policy Environment
The primary legislation is the Federal Food, Drug, and Cosmetic Act, Chapter V (21 U.S.C. 351 et seq.), as amended by the Medical Device User Fee and Modernization Act of 2002 and reauthorized through MDUFA V. The FDA's Center for Devices and Radiological Health enforces premarket classification, 21 CFR Part 820 quality system requirements, and Unique Device Identification rules under 21 CFR Part 801. The Quality Management System Regulation, aligning Part 820 with ISO 13485:2016, takes effect on February 2, 2026 and requires manufacturers to update design controls, supplier oversight, and complaint handling.
Upcoming changes cluster in 2026 and 2027. MDUFA VI negotiations between FDA and industry must conclude before MDUFA V authority expires on September 30, 2027. Commerce's Section 232 investigation into medical devices, initiated in September 2025 under the Trade Expansion Act of 1962, could impose tariffs on imported components. Compared with regional peers, U.S. premarket review is faster than the EU Medical Device Regulation (Regulation (EU) 2017/745), where notified body capacity constraints slow access, while Japan's PMDA pathway pairs review with national price listing by the Ministry of Health, Labour and Welfare.
Long-Term Policy Outlook for U.S. Orthopedics
By 2032, the largest policy shift will be the completed migration of elective arthroplasty to ambulatory settings under CMS payment rules, reshaping implant pricing and kit design. Bundled payment models such as the Comprehensive Care for Joint Replacement model, administered by the CMS Innovation Center, will continue rewarding low-cost episodes. This pushes manufacturers toward value-based contracts and outcome-linked pricing.
FDA policy will increasingly center on digital and AI-enabled orthopedic tools, including robotic surgical planning systems, under the agency's evolving guidance on AI-enabled device software functions. MDUFA VI will define review performance goals for FY2028–FY2032. Tariff outcomes from the Section 232 investigation will determine whether domestic manufacturing expansion accelerates in Indiana and Michigan.
Frequently Asked Questions
Market Segmentation
- Joint Reconstruction Implants
- Spinal Implants
- Trauma Fixation Devices
- Sports Medicine Devices
- Orthobiologics
- Hospitals
- Ambulatory Surgery Centers
- Orthopedic Clinics
- Veterans Affairs Facilities
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.